EVAX News and Press, Evaxion Biotech A/S

Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...

RALEIGH, NC / ACCESSWIRE / June 21, 2024 / iAccess Alpha's "Buyside Best Ideas Virtual Summer Conference" is taking place on June 25-26, 2024. The conference begins on Tuesday, June 25, with Company presentations beginning at 9:30 a.m. Eastern Time. Company presentations will be webcast live o...

A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s personalized cancer vaccine, EVX-01, in patients with metastatic melanoma The findings also demonstrate strong and clinically relevant immune responses ...

Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of Evaxion’s AI vaccine target discovery and design platform, AI-I...

2024-05-29 01:31:14 ET More on Evaxion Biotech ADS Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration Evaxion receives Nasdaq notification over minimum stockholders’ equity requirement Seeking Alpha’s Quant Rating on Evaxion Biotech...

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results. ...

EVX-01 induced positive clinically relevant immune responses in all assessed patients Booster immunizations tended to increase the immune response The observed immune responses were mediated by both CD4+ and CD8+ T-cells COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxio...

2024-05-10 17:11:41 ET More on Evaxion Biotech ADS Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration Seeking Alpha’s Quant Rating on Evaxion Biotech ADS Historical earnin...

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a...

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The presentation schedule is subject to change...